Ameriprise Financial Inc. Decreases Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Ameriprise Financial Inc. decreased its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 70.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,076 shares of the company's stock after selling 124,245 shares during the period. Ameriprise Financial Inc. owned about 0.07% of Kiniksa Pharmaceuticals worth $1,010,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in KNSA. Teacher Retirement System of Texas boosted its holdings in Kiniksa Pharmaceuticals by 7.1% during the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock worth $215,000 after buying an additional 719 shares in the last quarter. Martingale Asset Management L P raised its position in Kiniksa Pharmaceuticals by 1.9% during the fourth quarter. Martingale Asset Management L P now owns 49,360 shares of the company's stock worth $976,000 after acquiring an additional 900 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after acquiring an additional 1,004 shares during the last quarter. MetLife Investment Management LLC raised its position in Kiniksa Pharmaceuticals by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock worth $457,000 after acquiring an additional 1,374 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in Kiniksa Pharmaceuticals by 12.4% during the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company's stock worth $302,000 after acquiring an additional 1,680 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Stock Up 2.2%

Shares of NASDAQ:KNSA traded up $0.64 during trading on Thursday, reaching $29.52. The stock had a trading volume of 1,058,697 shares, compared to its average volume of 500,273. The business has a fifty day moving average price of $24.10 and a 200-day moving average price of $21.84. The stock has a market cap of $2.15 billion, a P/E ratio of -210.84 and a beta of 0.06. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $17.38 and a fifty-two week high of $29.75.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. The business had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company's revenue was up 72.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.25) earnings per share. As a group, equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insider Activity

In related news, CEO Sanj K. Patel sold 62,116 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $27.33, for a total value of $1,697,630.28. Following the completion of the sale, the chief executive officer now directly owns 96,674 shares in the company, valued at approximately $2,642,100.42. The trade was a 39.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ross Moat sold 18,259 shares of the business's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $20.29, for a total transaction of $370,475.11. Following the sale, the insider now owns 9,415 shares of the company's stock, valued at approximately $191,030.35. This represents a 65.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 391,014 shares of company stock valued at $10,101,143 over the last 90 days. Insiders own 54.57% of the company's stock.

Analyst Upgrades and Downgrades

KNSA has been the subject of a number of research reports. Wedbush restated an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Jefferies Financial Group lifted their target price on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Finally, Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 target price for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $38.80.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.